Investigation of the effect of metoclopramide on proliferation signal molecules in breast tissue

• Published in: International journal of experimental pathology Vol. 103; no. 3; pp. 83 - 89
• Main Authors: Umur, Nurcan, İldan Çalım, Selda, Yazıcı, Gülce Naz, Gurgen, Seren Gulsen
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01-06-2022; John Wiley and Sons Inc
• Subjects: BrdU; Breast; Breast feeding; breast tissue; breastfeeding; Breastfeeding & lactation; Bromodeoxyuridine - pharmacology; Cell Proliferation; Enzyme-linked immunosorbent assay; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Ki‐67; Lactation; Metoclopramide; Metoclopramide - adverse effects; Offspring; Original; Prolactin; Tissues; Tumors; Ki-67; prolactin; breastfeeding; metoclopramide; BrdU; breast tissue
• ISSN: 0959-9673; 1365-2613
• DOI: 10.1111/iep.12433

Metoclopramide (MCP) is a drug that has been widely used in recent years due to its hyperprolactinaemia effect on mothers during breastfeeding. The aim of this study was to investigate the proliferative changes that MCP may cause in the maternal breast tissue. In this study, 18 Wistar albino young–adult breastfeeding mothers with their offspring were divided into three groups: control group, low‐dose MCP‐applied group and high‐dose MCP‐applied group. The experiment was carried out during the lactation period and at the end of 21 days. Prolactin, BrdU and Ki‐67 breast tissue distributions were evaluated by immunohistochemistry, and tissue levels were evaluated biochemically by the ELISA method. According to ELISA and immunohistochemistry results in breast tissue, there was no significant difference between Ki‐67 and BrdU results in all groups. Metoclopramide did not change the expression of proliferation molecules Ki‐67 and BrdU in breast tissue. These results suggested that while metoclopramide increases breast proliferation, it does not have the risk of transforming the tissue into a tumour.